Filipino-founded clinical technology firm InterVenn Biosciences unveiled its state-of-the-art office in the Philippines to establish a bigger foothold in the Southeast Asian market. The expanded presence of the company in the country allows it to scale its software and IT capabilities to support current and future development and commercial activities. The company is headquartered in San Francisco, California, but the team that maintains the Artificial Intelligence (AI) technology is composed mostly of Filipino engineers residing in the Philippines.
“InterVenn has made significant progress in early cancer detection thanks to the brilliant and dedicated Filipino engineers we have on board. They help build and maintain the front end, back end, and cloud infrastructure of our next-generation liquid biopsy, as we all work together to reach a world where no one should ever be blindsided by disease,” InterVenn Biosciences co-founder and chief executive officer Aldo Carrascoso said.
InterVenn has developed the world’s first technology platform to interrogate and decode the glycoproteome which will help accelerate the shift from the healthcare industry’s traditional focus on disease management to the new preventive care health management. Glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes
Located at the Podium West Tower in Ortigas Center, Mandaluyong, InterVenn Biosciences’ offices will expand the local team’s roster of developers and engineers that form the backbone running the proprietary AI technology used in the company’s research. With more than 100 Filipinos working on the software engineering stream of InterVenn, the company also plans to hire more local talent to be used for their business expansion in the region.
“One hundred percent of our software is proudly Philippine-made. We started this venture with the goal of not just having the means of finding a cure and early detection for cancer, but to also showcase to everyone that we Filipinos can achieve this on a global scale,” said InterVenn Philippines general manager Axel Kornerup, who also proudly shared that InterVenn has been collaborating with local oncologists in running the VOCAL (InterVenn Ovarian Cancer Liquid Biopsy) testing program.
Having new facilities and cadre of researchers, the company has been aggressive in its recruitment and expansion to support the development and commercialization of DAWN, which they unveiled last month in the health industry’s largest conference for oncology, ASCO 2022. Its application on other tumor types is continuously being studied.
“Our research is a major step towards a truly universal healthcare. We’re proud to be making these phenomenal developments in the Philippines, and we look forward to working with more local stakeholders in the future,” said Carrascoso.
